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Abstract
Background: The incidence rates for adenocarcinoma of the esophagus are increasing while the prognosis has
only improved slightly. There is no apparent benefit in short- and long-term survival after different surgical strategies,
but surgery is associated with significant morbidity. The goal of this study is to prospectively assess the quality of life
and hospital costs after esophageal resections depending on the development of complications.
Methods: Prospective data was collected from 47 patients undergoing an esophageal resection for esophageal
cancer participating in the prospective LAParotomy or LAParoscopy and Adhesions (LAPAD) study (clinicaltrials.gov
registration number: NCT01236625). A comparison was made between patients who developed major complications
and minor or no complications regarding quality of life and hospital costs.
Results: Thirteen patients developed major complications while 34 patients developed only minor or no complications.
Patients with major complications had a mean hospital cost of $16,369 vs $12,409 for patients without or with minor
complications. We found no difference in quality of life between the two groups 6 months after surgery.
Conclusions: In our cohort, major complications did not seem to have a detrimental effect on postoperative quality of
life 6 months after surgery but they increased costs associated with esophageal resection.
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Synopsis
The aim of this study is to assess the quality of life and
hospital costs after esophageal resection with regard to
postoperative complications.
Background
The incidence rates for adenocarcinoma of the esopha-
gus increase in several Western countries, in part due to
increases in the prevalence of known risk factors such as
overweight and obesity. An estimated 482,300 new
esophageal cancer cases and 406,800 deaths occurred in
2008 worldwide [1].
The prognosis of esophageal cancer has only slightly
improved [2]. Surgical resection is the only treatment with
curative intent. Population-based studies from Europe
show 5-year survival rates after curatively intended
surgery for esophageal adenocarcinoma of 30.7 %. The
population-based stage-specific 5-year survival is 67, 33,
and 8 % in stages 0–I, II, and III, respectively. There is no
apparent benefit in short- and long-term survival between
the different surgical treatment strategies [3–7].
Especially for treatments with significant morbidity,
quality of life and hospital costs are important outcome
parameters. Surprisingly, accurate data on quality of life
and hospital costs and their association with complica-
tions following esophageal surgery are scarce [8–10].
The aim of this study is to prospectively assess the
quality of life and the costs of neo-adjuvant chemo
radiotherapy followed by an open esophageal resection
and the effect of a complicated postoperative course on
these outcomes.
Methods
For this study, we utilized data of consecutive patients
with open transhiatal resection of esophageal carcinoma
participating in the prospective LAParotomy or LAPar-
oscopy and Adhesions (LAPAD) study (clinicaltrials.gov
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registration number: NCT01236625). Detailed methods
of the LAPAD study are previously reported [11]. The
LAPAD study included all patients admitted to the surgi-
cal ward of the Radboud University Medical Center for
elective laparotomy or laparoscopy between June 2008
and June 2010. Detailed data on demographics, per- and
postoperative morbidity, hospital costs, and health-related
quality of life (HRQoL) of patients with curative surgery
for esophageal carcinoma was extracted from the LAPAD
database. Tumor histology and grade were reviewed in the
pathology report.
Patient selection
Patients with resection for esophageal carcinoma were
selected using the ICD-10 code at admission (C15*, C160,
or D130). For the purpose of differentiating between pa-
tient with or without major postoperative complication,
the Clavien-Dindo Classification of Surgical Complica-
tions was used [12]. Complications scored as grade II or
higher were considered major complications. HRQoL was
only studied in patients who filled in a questionnaire at
hospital admission or at 6 months follow-up.
Health-related quality of life
HRQoL was assessed using three validated questionnaires:
the short-form 36 (SF-36), the Duke Activity Status Index
(DASI), and the gastro-intestinal complaints list (GIC).
The structure and validity of the SF-36, DASI, and GIC
have been reported previously [13–15].
HRQoL questionnaires were completed the day before
surgery and at 6 months after discharge. Follow up at six
months was obtained by sending a postal questionnaire
with cover letter. Patients received a postal reminder
after 3 weeks and a telephonic reminder after an add-
itional 3 weeks.
Cost analysis
Costs analysis was performed in US dollars and included
only the direct hospital costs: operation costs, ward stay,
ICU stay, extra charges for parental and tube feeding,
postoperative diagnostic procedures, reoperation costs,
and blood products. Costs calculations were performed
using the guidelines for cost analysis from the Dutch
College of Health Insurance Companies using a top-down
approach. Operation costs were calculated based on total
anesthesia time with operating room costs of $1390/h in-
cluding personnel, material, and overhead costs. Total
costs for the surgical ward and ICU were $661 and $2289
per day, respectively, and included basic nutrition costs.
More than basic parental and tube feedings were calcu-
lated as extra nutritional costs. Diagnostic and reoperation
costs were calculated using the price lists for medical pro-
cedures by the Dutch College of Health Insurance Com-
panies of 2004. Medication costs and blood products costs
were calculated according to the standardized price list by
the Dutch College updated for June 2008 [16, 17].
Sample size calculation
Sample size calculation was based on the primary out-
come SF-36 score 6 months post-operatively. We defined
a difference of 10 % in the postoperative SF-36 score
between patients with severe complications compared to
patients with minor or no complications as relevant. The
population standard deviation was estimated at 10 %.
Based upon previous literature, the incidence of major
complications was estimated at 50 % [4]. Using these
assumptions, 32 patients were required to detect a 10 %
difference in SF-36 score 6 months post-operatively with
80 % power. Accounting for a 20 % loss to follow-up, a
minimum of 43 patients form the LAPAD database had to
be included.
Statistical analysis
Comparison was made between patients with (Clavien-
Dindo grade II or more) or without a major complication
(Clavien-Dindo grade 0 and I). Dichotomous data was an-
alyzed using χ2 test. Continuous data was presented as
means and tested using an independent T test. If continu-
ous data was not normally distributed, the Mann-Whitney
test was used for comparison of groups. A Wilcoxon
signed-rank test was used to evaluate statistical significant
differences between the pre- and postoperative data within
the two groups. We used the Kolmogorov-Smirnov test to
assess whether data was normally distributed. For the stat-
istical analysis of costs, we used a log transformation to
correct for a non-normal distribution in order to use an
independent T test. A p value < 0.05 was considered
significant. Statistical analysis was performed using SPSS
version 17.0 for Windows.
Results
Eight hundred forty-four planned operations were
screened for eligibility during the LAPAD study, and 750
operations were included. In 47 patients, the inclusion cri-
terion of admission and resection of esophageal carcinoma
was met. Data on postoperative morbidity and costs were
available in all patients. Of 47 included patients, 7 patients
did not complete all quality of life questionnaires, 1 pa-
tient did not complete the SF-36 and GIC questionnaire,
and 1 patient did not complete the GIC questionnaire.
Another 4 patients were not able to complete their quality
of life questionnaires after 6 months. Thus, data from 34
(72 %) patients was available for pre and postoperative
HRQoL assessment.
In-hospital mortality was 0 %. Thirteen patients (28 %)
developed complications of Clavien-Dindo grade II or
higher, and 34 (72 %) patients did not develop a compli-
cation or only a minor complication. There were no
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statistically significant differences between the two groups in
patient (Table 1) and tumor (results not shown) characteris-
tics. Particularly, co-morbidity did not differ between groups
(P= 0.30, Table 1). Of 13 patients, 1 developed 2 major com-
plications, which were heart failure and pneumonia. Pneu-
monia was present in 7 patients, 1 patient developed
anastomotic leakage, 1 fascial dehiscence, 1 nephrogenic
diabetes insipidus, and 1 postoperative hemorrhage. Two
patients with major complications developed in addition a
superficial wound infection classified as a minor complica-
tion. Of the 34 remaining patients (72 %), 29 had an
uncomplicated postoperative course, 5 had minor compli-
cations (Clavien-Dindo grade I); 1 patient had a urinary
tract infection, 2 needed additional diuretics because of
cardiac problems, and 2 developed a postoperative ileus.
The group with major complications had a mean
total days in hospital of 14.2 days compared to
10.3 days in the group without or with minor complications
(P = 0.04; Table 1).
There was a non-significant decline in QoL 6 months
post-operatively for all three questionnaires in the group
with major complications (Figs. 1–3). The decline in QoL
in the group without or with minor complications was sig-
nificant for the SF-36 and DASI (0.8 and 42.6 compared to
0.7 and 34.9; Figs. 2 and 3). The scores of the QoL ques-
tionnaires did not show any statistically significant differ-
ences between the two groups. No statistical differences
between the different domain scores of the SF-36 question-
naire and the different component scores of the GIC ques-
tionnaire were found, pre- and 6 months post-operatively,
Table 1 Patient characteristics and costs
Patient characteristics Total number of patients Patients with major complications Patients without major complications
Number of patients 47 (100 %) 13 (28 %) 34 (72 %)
Age 64.02 61.77 64.88 P = 0.27
Sex (M/F) 41/6 12/1 29/5 P = 0.66
BMI 26.09 27.10 25.71 P = 0.15
P-POSSUM 8.40 8.24 8.47 P = 0.95
Co-morbidity 37 (78.7 %) 11 (84.6 %) 26 (76.5 %) P = 0.30
Complications
Pneumonia 8 8 0
Anastomotic leakage 1 1 0
Postoperative hemorrhage 1 1 0
Platzbauch 1 1 0
Respiratory failure 1 1 0
Decompensatio cordis 1 1 0
Minor complications 7 2 5
Outcome
Re-interventions 3 3 0
In-hospital mortality 0 0 0
Surgical ward stay 9.12 11.30 8.29 P = 0.06
Medium-care stay 0.76 1.06 0.64 P = 0.41
IC-stay 1.52 1.78 1.41 P = 0.36
Total hospital stay 11.39 14.16 10.33 P = 0.04
TPV-requirement 1 (2.1 %) 1 (7.7 %) 0 (0 %) P = 0.28
Number of readmittances to hospital
5 (10.6 %) 0 (0 %) 5 (14.4 %) P = 0.30
Costs
Operation 4062 4042 P = 0.73
Surgical ward 5379 3944 P = 0.15
Medication 638 319 P = <0.01
Diagnostic 433 251 P = 0.04
Microbiology 119 27 P = 0.04
Total cost 16,369 12,409 P = 0.02
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Fig. 1 Results of the pre- and postoperative SF-36 questionnaire
Fig. 2 Results of the pre- and postoperative GIC questionnaire
Strik et al. World Journal of Surgical Oncology  (2015) 13:266 Page 4 of 6
between both groups (results not shown). The group with
major complications did not show a greater decline in QoL
at 6 months post-operatively in comparison to the group
without or with minor complications.
Costs are presented in Table 1. Total costs reached a
significant difference; $12,409 for the group without or
with minor complications vs $16,369 for the group with
major complications (p = 0.02). This was predomin-
antly based on higher costs for microbiology, $27 vs
$119 (p = 0.04), costs associated with medication,
$319 vs $638 (p = <0.01), and diagnostic costs, $251
vs $433 (p = 0.04). There was a trend towards higher
costs for the surgical ward (p = 0.15).
Discussion
This is the first study to our knowledge that prospect-
ively investigated the relation between postoperative
complications and quality of life. It demonstrates that
health-related quality of life declines after esophageal
resection for carcinoma but irrespectively of the devel-
opment of early postoperative major complications. We
showed higher costs and a longer hospital stay associ-
ated with major complications.
Our study showed a 0 % in-hospital mortality, a 17 % in-
cidence of pneumonia, and a low overall incidence of
complications compared to the literature. A recent ran-
domized controlled found a 12 % incidence of pneumonia
for patients undergoing minimal invasive esophageal
resection [18] while open (transhiatal or transthoracic)
esophageal resection is associated with a 27 and 57 % inci-
dence of pulmonary complications [4]. The low complica-
tion rate in our institute might be explained by a dedicated
multi-disciplinary team approach. The pre-operative work-
up strategy in our center consists of pre-operative dietary
measures and physiotherapy combined with admittance to
the ICU for goal directed hemodynamic and respiratory
optimization the day before surgery. Complications and in-
hospital mortality rates remained comparably low in the
years after study closure.
The development of postoperative complications did
not result in a significant decrease in QoL in this study.
This conclusion should be interpreted with some caution
as the low incidence of major complications resulted in a
smaller group of patients that developed major compli-
cations than accounted for in our sample size calcula-
tion. However, we did not find a statistical significant
difference between the groups; on the contrary, the
population estimates of SF-36, gastro-intestinal com-
plaints score, and DASI-score were highly comparable
between the groups. The most common complication
was a pneumonia, and although this is a major compli-
cation with a negative impact on 5-year survival [19],
patients recover completely when treated adequately
[20]. It is possible that complications requiring re-
intervention and or admission to the intensive care unit
have a more detrimental effect on QoL, but our study
could not demonstrate this effect because of the low
incidence of these complications and a high standard
deviation in the SF-36 score.
We showed that there is a statistically significant differ-
ence in total hospital costs for patients who developed
major complications. Kuppusamy et al. also showed a
difference in costs between patients who developed com-
plications and who did not develop complications under-
going esophageal resection [21]. However, the study
population consisted of four small groups of 15 patients
Fig. 3 Results of the pre- and postoperative DASI questionnaire
Strik et al. World Journal of Surgical Oncology  (2015) 13:266 Page 5 of 6
undergoing different treatment regimens. Kuppusamy et
al. used a financial cost-accounting system that also
encompassed indirect costs. These indirect costs consist
of a complex association of all overhead costs, including
billing, information systems, finance, and administration.
These costs are hospital specific and not applicable in
general. Although actual costs may vary per country, our
cost calculation utilized only the direct true hospital costs,
making our results universally applicable. Our study found
in particular a difference in diagnostic and medication
costs. This is because most patients with a major compli-
cation developed a pneumonia treated with antibiotics.
A limitation of this study is that it did not use the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ)-
OES18 because the LAPAD study included all types of
laparotomies. However, the gastro-intestinal complaints
questionnaire has six items that are similar to the EORTC
QLQ-OES18, and it is a validated QoL questionnaire.
Although our study population is small, it is a consecutive
group of patients with characteristics encountered in all
hospitals that perform esophagectomies. Therefore, we
believe that our results apply to all patients undergoing an
esophageal resection for cancer in hospitals with a similar
quality of care.
Conclusions
In our cohort, major complications did not seem to have a
detrimental effect on postoperative quality of life 6 months
after surgery but they increased costs associated with
esophageal resection.
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